Akutdiagnostik und Akuttherapie des ischämischen Insultes

Zusammenfassung

In Deutschland treten pro Jahr etwa 200 000 erstmalige Schlaganfälle, zumeist ischämische Insulte auf. Durch große randomisierte Studien ist der therapeutische Nutzen der Behandlung auf einer Schlaganfall-Spezialstation (Stroke Unit) und die Rekanalisationstherapie durch systemische Thrombolyse belegt. Die Diagnostik umfasst neben der Erhebung des neurologischen Befundes eine zerebrale Bildgebung mittels CT oder MRT mit CT-/MR-Angiographie, Ultraschall der hirnversorgenden Arterien, EKG und Langzeit-EKG und – wenn indiziert – transösophageale Echokardiographie. Die frühe Sekundärprävention besteht zumeist aus Acetylsalicylsäure, im weiteren Verlauf orientiert sich die Sekundärprophylaxe an der Pathophysiologie. Bei hämodynamisch oder arterio-arteriell bedingten zerebralen Infarkten durch hochgradige Stenosen der A. carotis interna erfolgt eine Carotisendarterektomie oder Stent-gestützte Angioplastie. Bei kardialer Embolie aufgrund von Vorhofflimmern wird nach der Akutphase eine orale Antikoagulation mit Vitamin K-Antagonisten oder neuen oralen Antikoagulantien eingeleitet. Bei den übrigen Patienten sowie in der Akutphase erfolgt die Sekundärprävention durch Thrombozytenfunktionshemmer.

Abstract

The incidence of first stroke in Germany is about 200.000, most of which are ischemic. The benefit of stroke unit treatment and systemic thrombolysis has been shown in large randomized trials. Diagnostic work-up besides neurologic examination includes cerebral imaging by CT or MR imaging including angiography, ultrasound of brain supplying arteries, ECG and Holter ECG and – if indicated – transesophageal echocardiography. Aspirin is the cornerstone of early secondary prevention in the acute phase, thereafter secondary prevention is determined by stroke etiology. Carotid endarterectomy or stent-assisted angioplasty are indicated in patients with hemodynamic or arterio-arterial stroke etiologies due to high-grade carotid stenosis. For cardioembolism due to atrial fibrillation, oral anticoagulation with vitamin K-antagonists or new oral anticoagulants should be started after the acute phase. In patients with non-cardioembolic stroke etiologies, platelet inhibitors are used for secondary prevention.

Schlüsselwörter

Schlaganfall - Hirninfarkt - zerebrale Ischämie - Bildgebung - Sekundärprophylaxe - Antikoagulation - Thrombozytenfunktionshemmer

Keywords

Stroke - ischemic stroke - cerebral ischemia - imaging - secondary stroke prevention - anticoagulation - platelet inhibitors

• Literatur

• 1 Adams Jr HP, Effron MB, Torner J et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008; 39: 87-99
• 2 Amarenco P, Bogousslavsky J, Callahan A et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-559
• 3 Blanco M, Nombela F, Castellanos M et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007; 69: 904-910
• 4 Bonati LH, Dobson J, Algra A et al. Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. Lancet 2010; 376: 1062-1073
• 5 Brott TG, Hobson 2nd RW, Howard G et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363: 11-23
• 6 CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997; 349: 1641-1649
• 7 Chan DK, Cordato D, O'Rourke F et al. Comprehensive stroke units: a review of comparative evidence and experience. Int J Stroke 2012; doi:
• 8 Dengler R, Diener HC, Schwartz A et al. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010; 9: 159-166
• 9 Diener H, Bogousslavsky J, Brass L et al. Acetylsalicylic acid on a background of clopidogrel in high-risk patients randomised after recent ischaemic stroke or transient ischaemic attack: The MATCH trial results. Lancet 2004; 364: 331-334
• 10 Diener HC, Weber R, Weimar C et al. Secondary prevention in the acute and early chronic phase after ischaemic stroke and transient ischaemic attacks with antiplatelet drugs – is antiplatelet monotherapy still reasonable?. Int J Clin Pract 2011; 65: 531-535
• 11 Diener HC, Weimar C Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart, New York: Georg Thieme Verlag; 2012
• 12 Engelter ST, Dallongeville J, Kloss M et al. Thrombolysis in Cervical Artery Dissection – Data from the Cervical Artery Dissection and Ischaemic Stroke Patients (CADISP) database. Eur J Neurol 2012; 19: 1199-1206
• 13 European Stroke Organisation (ESO) Executive Committee. ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507
• 14 Eyding J, Weimar C, Brassel F et al. Das „Neurovaskuläre Netz Ruhr“. Akt Neurol 2012; 39: 404-411
• 15 Foley N, Salter K, Teasell R. Specialized stroke services: a meta-analysis comparing three models of care. Cerebrovasc Dis 2007; 23: 194-202
• 16 Furlan AJ, Reisman M, Massaro J et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012; 366: 991-999
• 17 Heuschmann PU, Neuhauser HK, Endres M. Entwicklung von Mortalitat und Morbiditat vaskularer Erkrankungen: Unterschiede zwischen koronarer Herzerkrankung und Schlaganfall. Nervenarzt 2011; 82: 145-146
• 18 I S. T. Collaborative Group. . Sandercock P, Wardlaw JM et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379: 2352-2363
• 19 International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-1581
• 20 Kennedy J, Hill MD, Ryckborst KJ et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007; 6: 961-969
• 21 Knöß N, Jansen O, Brenck J et al. Lokale Therapie des ischämischen Insults: Mechanische Thrombektomie. Aktuelle Neurologie 2012; 39: 180-185
• 22 Paciaroni M, Agnelli G, Micheli S et al. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007; 38: 423-430
• 23 Rerkasem K, Rothwell PM. Carotid endarterectomy for symptomatic carotid stenosis. . Cochrane Database Syst Rev 2011; CD001081
• 24 Riedel CH, Zimmermann P, Jensen-Kondering U et al. The importance of size: successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length. Stroke 2011; 42: 1775-1777
• 25 Ringelstein EB, Muller-Jensen A, Nabavi DG et al. Erweiterte Stroke-Unit. Nervenarzt 2011; 82: 778-784
• 26 Sandset EC, Bath PM, Boysen G et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011; 377: 741-750
• 27 Wardlaw JM, Murray V, Berge E et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; 379: 2364-2372